Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) issued its earnings results on Thursday. The company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.02), Zacks reports.
Autolus Therapeutics Stock Down 2.2 %
Shares of AUTL stock traded down $0.03 on Friday, reaching $1.32. The company's stock had a trading volume of 2,763,549 shares, compared to its average volume of 1,451,632. Autolus Therapeutics has a 12-month low of $1.11 and a 12-month high of $5.00. The stock's 50 day simple moving average is $1.53 and its 200-day simple moving average is $2.26. The company has a market capitalization of $351.24 million, a P/E ratio of -1.09 and a beta of 1.77.
Wall Street Analyst Weigh In
Several research analysts recently commented on AUTL shares. Needham & Company LLC reaffirmed a "buy" rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a report on Thursday, April 10th. Truist Financial cut their price target on Autolus Therapeutics from $11.00 to $10.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Finally, Wells Fargo & Company decreased their price objective on Autolus Therapeutics from $8.00 to $6.00 and set an "overweight" rating on the stock in a research note on Friday, March 21st. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, Autolus Therapeutics presently has an average rating of "Buy" and an average target price of $9.32.
Get Our Latest Stock Report on AUTL
Autolus Therapeutics Company Profile
(
Get Free Report)
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Autolus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Autolus Therapeutics wasn't on the list.
While Autolus Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
